Salarius Pharmaceuticals (SLRX) Competitors $0.78 -0.22 (-21.69%) Closing price 04:00 PM EasternExtended Trading$0.76 -0.03 (-3.55%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLRX vs. ENSC, QLGN, SPRB, VIVS, MTNB, ORGS, GLTO, ADIL, GRI, and REVBShould you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include Ensysce Biosciences (ENSC), Qualigen Therapeutics (QLGN), Spruce Biosciences (SPRB), VivoSim Labs (VIVS), Matinas Biopharma (MTNB), Orgenesis (ORGS), Galecto (GLTO), Adial Pharmaceuticals (ADIL), GRI Bio (GRI), and Revelation Biosciences (REVB). These companies are all part of the "pharmaceutical products" industry. Salarius Pharmaceuticals vs. Its Competitors Ensysce Biosciences Qualigen Therapeutics Spruce Biosciences VivoSim Labs Matinas Biopharma Orgenesis Galecto Adial Pharmaceuticals GRI Bio Revelation Biosciences Salarius Pharmaceuticals (NASDAQ:SLRX) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk. Does the media prefer SLRX or ENSC? In the previous week, Salarius Pharmaceuticals had 11 more articles in the media than Ensysce Biosciences. MarketBeat recorded 12 mentions for Salarius Pharmaceuticals and 1 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 1.89 beat Salarius Pharmaceuticals' score of 0.19 indicating that Ensysce Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Salarius Pharmaceuticals Neutral Ensysce Biosciences Very Positive Do insiders and institutionals have more ownership in SLRX or ENSC? 11.9% of Salarius Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are owned by institutional investors. 1.2% of Salarius Pharmaceuticals shares are owned by insiders. Comparatively, 7.9% of Ensysce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, SLRX or ENSC? Salarius Pharmaceuticals has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Is SLRX or ENSC more profitable? Salarius Pharmaceuticals has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -109.49%. Ensysce Biosciences' return on equity of -192.54% beat Salarius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Salarius PharmaceuticalsN/A -324.13% -174.40% Ensysce Biosciences -109.49%-192.54%-121.77% Which has preferable valuation and earnings, SLRX or ENSC? Ensysce Biosciences is trading at a lower price-to-earnings ratio than Salarius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSalarius PharmaceuticalsN/AN/A-$5.58M-$4.82-0.16Ensysce BiosciencesN/AN/A-$7.99M-$6.54-0.32 SummarySalarius Pharmaceuticals beats Ensysce Biosciences on 6 of the 11 factors compared between the two stocks. Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLRX vs. The Competition Export to ExcelMetricSalarius PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.67M$2.46B$5.59B$9.53BDividend YieldN/A1.77%4.71%4.03%P/E Ratio-0.169.4927.9619.93Price / SalesN/A427.91389.5465.88Price / CashN/A165.5736.3258.75Price / Book0.824.968.375.77Net Income-$5.58M$31.62M$3.25B$259.10M7 Day Performance11.83%-3.27%-2.50%-3.41%1 Month Performance-12.62%9.78%7.98%8.53%1 Year Performance-76.28%-5.75%34.65%15.75% Salarius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLRXSalarius Pharmaceuticals0.3001 of 5 stars$0.78-21.7%N/A-73.2%$1.67MN/A-0.1620Trending NewsGap DownHigh Trading VolumeENSCEnsysce Biosciences0.9559 of 5 stars$2.17+1.9%N/A-67.4%$5.05M$5.21M-0.3310QLGNQualigen TherapeuticsN/A$3.07+2.0%N/A-78.0%$4.92M$4.98M0.0050News CoverageGap DownSPRBSpruce Biosciences2.1263 of 5 stars$0.12+5.7%$1.75+1,404.7%-77.6%$4.91M$4.91M-0.1220Stock SplitVIVSVivoSim LabsN/A$1.98+4.8%N/AN/A$4.91M$140K-0.1920MTNBMatinas BiopharmaN/A$0.95-0.6%N/AN/A$4.85MN/A-0.2030ORGSOrgenesis1.7241 of 5 stars$1.01-2.9%N/AN/A$4.85M$662K0.00150Upcoming EarningsGap UpGLTOGalecto3.6995 of 5 stars$3.60+0.3%$10.00+177.8%-74.4%$4.74MN/A-0.2340ADILAdial Pharmaceuticals2.7131 of 5 stars$0.51+12.4%$8.00+1,477.9%-42.8%$4.71MN/A-0.3520GRIGRI Bio2.9121 of 5 stars$1.99+9.3%$22.00+1,005.5%-85.9%$4.54MN/A-0.171Gap UpREVBRevelation Biosciences1.8712 of 5 stars$3.06+3.7%N/A-96.7%$4.53MN/A-0.0110Gap UpHigh Trading Volume Related Companies and Tools Related Companies ENSC Competitors QLGN Competitors SPRB Competitors VIVS Competitors MTNB Competitors ORGS Competitors GLTO Competitors ADIL Competitors GRI Competitors REVB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLRX) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredStrange Investment Secret Predicts Market's Next Move?A strange market signal discovered before the Great Depression has predicted nearly every major financial even...Weiss Ratings | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLRX Stock Alerts